Notice of EGM
The Board of Directors of ChronTech has resolved to convene an EGM to be held on 6 May 2013 at 2.00 pm, please find the notice attached (only available in Swedish). For more information, please contact: Anders Vahlne, CEO and Head of Research, ChronTech Pharma AB Mobile phone: +46 709 28 05 28,E-mail: anders.vahlne@ki.se About ChronTech ChronTech develops the therapeutic DNA vaccines ChronVac-C® and ChronVac-B drugs against chronic hepatitis C virus and hepatitis B virus infections, i.e. chronic infections with jaundice causing viruses which can lead to liver cirrhosis and